logo
Plus   Neg
Share
Email

Eli Lilly Shares To Be Delisted From Euronext Paris On Oct. 31 - Quick Facts

Eli Lilly And Co. (LLY) said the Board of Euronext Paris has approved the company's request to delist shares. The company's decision was due to the very low trading volume, costs and administrative requirements related to its secondary listing. The shares will remain listed on the NYSE.

Eli Lilly will provide a voluntary sales facility procedure on the NYSE to its Euronext shareholders. BNP Paribas Securities Services, acting as centralizing agent, will calculate the average sale price of the Lilly shares. Lilly will pay the fees for the centralization and the brokerage fee under the sales procedure. Shareholders who do not wish to sell their Lilly shares will be able to trade only on the NYSE following the delisting.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>